Alice Marceau-Renaut

List of Publications by Year
in descending order

33 papers	1,041 citations	567281 15 h-index	477307 29 g-index
34 all docs	34 docs citations	34 times ranked	1698 citing authors

#	Article	IF	Citations
1	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2017, 35, 185-193.	1.6	227
2	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood, 2016, 127, 2451-2459.	1.4	198
3	IDH1/2but notDNMT3Amutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 2015, 6, 42345-42353.	1.8	92
4	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood, 2020, 135, 542-546.	1.4	62
5	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. Blood, 2018, 132, 187-196.	1.4	54
6	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia, 2019, 33, 348-357.	7.2	44
7	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. HemaSphere, 2018, 2, e31.	2.7	40
8	Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia, 2011, 25, 1661-1664.	7.2	39
9	Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica, 2018, 103, 822-829.	3.5	36
10	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplantation, 2017, 52, 539-543.	2.4	30
11	Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Review of Hematology, 2015, 8, 43-56.	2.2	28
12	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1â€RUNX1T1 fusion quantification on genomic DNA. American Journal of Hematology, 2014, 89, 610-615.	4.1	21
13	Detection of a new heterozygous germline <scp>ETV</scp>6 mutation in a case with hyperdiploid acute lymphoblastic leukemia. European Journal of Haematology, 2018, 100, 104-107.	2.2	18
14	Myelodysplastic syndrome (<scp>MDS</scp>) with isolated trisomy 8: a type of <scp>MDS</scp> frequently associated with myeloproliferative features? A report by the Groupe Francophone des MyÂ©lodysplasies. British Journal of Haematology, 2018, 182, 843-850.	2.5	18
15	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia, 2016, 30, 1416-1418.	7.2	16
16	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. Blood, 2019, 134, 2414-2416.	1.4	14
17	Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica, 2019, 104, 1150-1155.	3.5	14
18	Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. HemaSphere, 2019, 3, e203.	2.7	13

#	Article	IF	Citations
19	Classification of <scp>CEBPA</scp> mutated acute myeloid leukemia by <scp>GATA2</scp> mutations. American Journal of Hematology, 2015, 90, E93-4.	4.1	12
20	Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group. Blood, 2014, 124, 1062-1062.	1.4	12
21	Restoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximab. Annals of Hematology, 2015, 94, 1247-1249.	1.8	9
22	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leukemia Research, 2015, 39, 1443-1447.	0.8	9
23	Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome. Haematologica, 2018, 103, e274-e276.	3.5	9
24	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. Leukemia, 2018, 32, 1878-1882.	7.2	8
25	Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial. Haematologica, 2021, 106, 908-912.	3.5	8
26	Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. Leukemia Research, 2018, 71, 67-74.	0.8	4
27	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. Leukemia, 2018, 32, 2066-2069.	7.2	4
28	Posttransplantation relapse of pediatric chronic myelomonocytic leukemia cured using donor lymphocyte infusion. Pediatric Blood and Cancer, 2018, 65, e26808.	1.5	1
29	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. Blood, 2014, 124, 2327-2327.	1.4	1
30	Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-RUNX1T1 Fusion Quantification On Genomic DNA. Blood, 2013, 122, 1353-1353.	1.4	0
31	Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia. Blood, 2014, 124, 2360-2360.	1.4	0
32	Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis. Blood, 2014, 124, 1007-1007.	1.4	0
33	Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial. Blood, 2016, 128, 1676-1676.	1.4	0